| Trial registration number
|
NCT04703036 |
Full text link
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04703036
|
First author
Last imported at : May 11, 2023, 8 a.m.
Source : ClinicalTrials.gov
|
Rajagopal V Sekhar
|
Contact
Last imported at : May 11, 2023, 8 a.m.
Source : ClinicalTrials.gov
|
Not reported
|
Registration date
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
2021-01-11
|
Recruitment status
Last imported at : May 11, 2023, 8 a.m.
Source : ClinicalTrials.gov
|
Not recruiting
|
Study design
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
- age 55-85y;
- diagnosis of covid-19;
- hospitalized patients.
|
Exclusion criteria
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
- active heart disease or active cancer at time of recruitment;
- patients in intensive care unit at the time of recruitment;
- patents with alanine transaminase and aspartate transaminase greater than 5 times the
upper limit of normal at any time;
- patients requiring >4l per minute of oxygen support at the time of recruitment.
|
Number of arms
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Baylor College of Medicine
|
Inclusion age min
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
55
|
Inclusion age max
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
85
|
Countries
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
United States
|
Type of patients
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Moderate/severe disease at enrollment
|
Severity scale
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
4: Moderate/severe disease at enrollment
|
Total sample size
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
64
|
primary outcome
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Change in Glutathione concentrations;Change in Interleukein 6 concentrations;Change in Ordinal scale
|
Notes
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov
|
Phase 1
|
Arms
Last imported at : Jan. 13, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 1525, "treatment_name": "Glycine+n-acetylcysteine", "treatment_type": "Vitamins and dietary supplements+respiratory agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
|